CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
1-Year Return
31.81%
This Quarter Return
-2.22%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$1.07B
AUM Growth
+$5.91M
(+0.55%)
Cap. Flow
+$63.5M
Cap. Flow
% of AUM
5.91%
Top 10 Holdings %
Top 10 Hldgs %
36.46%
Holding
509
New
13
Increased
172
Reduced
270
Closed
23
Top Buys
| 1 |
Apple
AAPL
|
$12.2M |
| 2 |
Amazon
AMZN
|
$8.41M |
| 3 |
Microsoft
MSFT
|
$6.53M |
| 4 |
Analog Devices
ADI
|
$4.63M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
$3.68M |
Top Sells
| 1 |
iShares Silver Trust
SLV
|
$7.9M |
| 2 |
ProShares Ultra Gold
UGL
|
$7.89M |
| 3 |
Arista Networks
ANET
|
$6.7M |
| 4 |
Gilead Sciences
GILD
|
$5.26M |
| 5 |
TSMC
TSM
|
$3.61M |
Sector Composition
| 1 | Technology | 36.93% |
| 2 | Healthcare | 24.36% |
| 3 | Consumer Discretionary | 11.82% |
| 4 | Communication Services | 11.17% |
| 5 | Consumer Staples | 4.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
351
KalVista Pharmaceuticals
KALV
$783M
| $114K | 0.01% |
9,912
-417
| -4% | -$4.81K |
|
352
AnaptysBio
ANAB
$615M
| $114K | 0.01% |
6,151
-301
| -5% | -$5.6K |
|
353
Trevi Therapeutics
TRVI
$866M
| $113K | 0.01% |
17,925
+1,627
| +10% | +$10.2K |
|
354
Kura Oncology
KURA
$728M
| $107K | 0.01% |
16,198
-291
| -2% | -$1.92K |
|
355
MeiraGTx Holdings
MGTX
$636M
| $106K | 0.01% |
15,676
-895
| -5% | -$6.07K |
|
|
SAGE
356
DELISTED
Sage Therapeutics
SAGE
| $98K | 0.01% |
12,332
-639
| -5% | -$5.08K |
|
357
abrdn Physical Silver Shares ETF
SIVR
$2.53B
| $97.5K | 0.01% |
3,000
| – | – |
|
358
Arvinas
ARVN
$585M
| $96.8K | 0.01% |
13,794
-776
| -5% | -$5.45K |
|
359
Omeros
OMER
$289M
| $95.5K | 0.01% |
11,624
-663
| -5% | -$5.45K |
|
360
Savara
SVRA
$655M
| $95.4K | 0.01% |
34,424
-1,966
| -5% | -$5.45K |
|
361
Tyra Biosciences
TYRA
$682M
| $94.4K | 0.01% |
10,150
-580
| -5% | -$5.39K |
|
362
UroGen Pharma
URGN
$885M
| $93.6K | 0.01% |
8,464
-484
| -5% | -$5.35K |
|
363
HUTCHMED
HCM
$2.73B
| $93.6K | 0.01% |
6,221
-356
| -5% | -$5.35K |
|
364
Relay Therapeutics
RLAY
$710M
| $89.1K | 0.01% |
34,003
-1,488
| -4% | -$3.9K |
|
365
Cullinan Oncology
CGEM
$415M
| $88.8K | 0.01% |
11,737
-609
| -5% | -$4.61K |
|
366
Theravance Biopharma
TBPH
$722M
| $88.1K | 0.01% |
9,864
-563
| -5% | -$5.03K |
|
367
Precigen
PGEN
$1.36B
| $87.5K | 0.01% |
58,744
-3,355
| -5% | -$5K |
|
368
Phibro Animal Health
PAHC
$1.59B
| $87.1K | 0.01% |
4,079
-233
| -5% | -$4.98K |
|
369
MindMed
MNMD
$696M
| $86K | 0.01% |
14,709
-840
| -5% | -$4.91K |
|
370
Phathom Pharmaceuticals
PHAT
$907M
| $86K | 0.01% |
13,715
-784
| -5% | -$4.92K |
|
|
MESO
371
Mesoblast
MESO
$1.84B
| $85.1K | 0.01% |
6,822
+46
| +0.7% | +$574 |
|
372
Keros Therapeutics
KROS
$638M
| $82.9K | 0.01% |
8,136
-453
| -5% | -$4.62K |
|
373
iShares Russell Top 200 Growth ETF
IWY
$14.9B
| $82.5K | 0.01% |
391
| – | – |
|
|
VERV
374
DELISTED
Verve Therapeutics
VERV
| $81.4K | 0.01% |
17,811
-141
| -0.8% | -$644 |
|
375
Zevra Therapeutics
ZVRA
$498M
| $80.2K | 0.01% |
10,706
-612
| -5% | -$4.58K |
|